Stryker invests $400M in CMR Surgical — and takes exclusive US sales rights to Versius
From the Robots digest for 2026-10-15
What happened: Stryker is investing $400 million in CMR Surgical and plans to serve as the exclusive sales agent in the United States for CMR's Versius robotics portfolio (The Robot Report, published October 15, 2026, ~12:54 PM ET).
What's genuinely new: Development of robots — Surgical robotics consolidation — the thread opened September 6 on the September 3–5 burst of medtech money into surgical robotics (Medtronic's $700M investment in Cornerstone Robotics, Enovis's $180M acquisition of eCential Robotics, ~$880M in three days) with an explicit watch for the next deal. Six weeks later the next deal arrives, and it is Stryker — itself a major medtech incumbent — buying stake-plus-distribution rather than an outright acquisition: investment money paired with exclusive US channel rights to the Versius portfolio. A different shape than either the Medtronic investment or the Enovis acquisition on file.
Watch: Whether the $400M stake converts to a full acquisition, the terms of the exclusive US sales agency, Versius's US regulatory and commercial path under Stryker, and whether CMR retains other channels.
Links: The Robot Report — Stryker invests $400M into CMR Surgical